Thank you for submitting your manuscript for consideration by the EMBO Journal. Please let me first apologise for the slight delay in getting back to you with a decision: this was primarily due to some difficulty in finding three appropriate referees. However, we have now received comments from three reviewers, which are enclosed below. As you will see, all three referees express interest in your work, but all also raise a number of substantial concerns that would need to be addressed by a major revision of your study, before we could consider publication here. Their reports are explicit, so I see little need to go into details here, but if you have any questions or comments about the revision, please don't hesitate to get in touch.
Given the referees' positive recommendations, I would like to invite you to submit a revised version of the manuscript, addressing the comments of all three reviewers. I should add that it is EMBO Journal policy to allow only a single round of revision, and acceptance of your manuscript will therefore depend on the completeness of your responses in this revised version. When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process, please visit our website: http://www.nature.com/emboj/about/process.html
We generally allow three months as standard revision time. As a matter of policy, competing manuscripts published during this period will not negatively impact on our assessment of the conceptual advance presented by your study. However, we request that you contact the editor as soon as possible upon publication of any related work, to discuss how to proceed. Should you foresee a problem in meeting this three-month deadline, please let us know in advance and we may be able to grant an extension.
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
Yours sincerely, Editor
The EMBO Journal REFEREE REPORTS Referee #1 (Remarks to the Author):
The manuscript from Zhu and Sarkar demonstrates an integration of signaling pathways that is apparently important for Sendai virus activation of some IFN stimulated genes. They demonstrate that Sendai activates PKCa, which in turn activates HDAC6 in the cytosol, which in turn deacetylates beta catenin, allowing it to move to the nucleus and act as a transcriptional co-factor for IRF3. This is a potentially significant finding, revealing a new layer of regulation in the antiviral response. It also ties together some seemingly unrelated prior observations, such as the essential role for HDAC6 in the induction of IFN beta gene expression and the recently uncovered role for beta catenin mediating IRF3 signaling.
For the most part, the data clearly support the author's conclusions and ultimately the model provided. Nonetheless, some questions remain to be addressed to fully appreciate the significance and generality of the findings.
1. The results indicate that this pathway is "cell type specific", suggesting that there is more to understand about when and where this new pathway is required or activated. The other side of this same issue is whether the pathway is "pathogen type specific". Only Sendai is used (other than VSV-GFP as a reporter) to induce the PKC-dependent response. Is this a common pathway activated by negative strand RNA viruses or only paramyxoviruses? What about flu, HSV, etc? 2. Similarly, there are many means to induce the IFN response in cells, such as transfection with poly IC or 5'ppp RNAs, and certain dsDNAs. Do these require the PKC b-cat pathway? What about TLR pathways activated by viral nucleic acids or other ligands? Is PKC required for these IFN activating stimuli? 3. The authors suggest that Ca++ mobilization might be a primary inducer for this response. It seems simple enough to test if Sendai does activate Ca++. Is the PKC-b-cat pathway activated by manipulating Ca++ pathways with ionophores, etc? It is intriguing to imagine one side of the figure is activated by Ca++ and the other by RNA.
4. The speculation on pg 16 about IRF8 compensating for b-cat should be supported if there is a sound basis, or simply removed.
5. Panel 6C very poorly represents a loss of acetylated b-cat after 8hrs of Sendai infection. It is not a robust response and seems unlikely to have a significant biological effect. This should be quantified.
6. All the experiments using nuclear fractionation have control panels illustrating nuclear components, but there is no indication of how much cytosolic contamination is in the nuclear preparations, important to rule out for these experiments. Please provide additional controls.
Referee #2 (Remarks to the Author):
The authors show that transcriptional induction of ISREs and IFN by Sendai virus infection is inhibited with pharmacological inhibitors of PKCalpha and by siRNA. This is not due to an inhibition of IRF3 activation, as silencing PKCalpha did not result in a defect on Sendai virusmediated IRF3 phosphorylation or translocation to the nucleus. However, IRF3 does not bind to a responsive promoter as measured by ChIP when PKCalpha is silenced. Silenced cells also supported higher replication of VSV. The authors demonstrate that virus infection induced interaction of PKCalpha with HDAC6 and beta-catenin, suggesting a model in which PKCalpha stimulates HDAC6 by phosphorylation, which in turn stimulates beta-catenin by deacetylation, leading to translocation of beta-catenin to the nucleus where it helps IRF3 to mediate promoter activation. This model is strongly supported by the experimental evidence in this manuscript, and it adds relevant and highly significant information to our understanding of the pathways leading to antiviral immunity.
Specific comments 1. Fig. 1E . It is claimed in this figure that Sendai virus infection induces PKCalpha activation as detected by phosphorylation. However, there are considerable high levels of phosphorylated PKCalpha prior to infection, and the increase during viral infection is very subtle. These results are not convincing.
2. The translocation data of Fig. 1F are also unconvincing, and importantly, not correlated with the subtle changes in phosphorylated PKCalpha in Fig. 1E 3. In the same line, Fig 5C shows that there is a decrease in phosphorylation of HDAC when PKCalpha is silenced even in the absence of Sendai virus infection (compare lines 1 to 3). This would indicate that prior to infection and activation, endogenous PKCalpha has already primed HDAC/betacatenin, and that this pathway, although needed for IRF3-mediated transcription, may not be so dependent on viral activation, at least in the cells used in this study.
The model in Fig 7C does not take into account the constitutively association of beta-catenin with PKCalpha
Referee #3 (Remarks to the Author):
In the present study, the authors investigated the role of PKC-alpha in IRF3-dependent gene transcription. Pharmacal PKC-alpha inhibitor or PKC-alpha knockdown inhibited Sev-induced IRF3-dependent gene expression. PKC-alpha knockdown did not affected Sev infection-induced IRF3 phosphorylation and nuclear translocation, but inhibited Sev infection-induced IRF3 binding to its target gene promoters. Further experiments showed that PKC-alpha phosphorylated HDAC6 and thus promoted deacetylation of beta-catenin and binding of beta-catenin to the promoter of IRF3-dependent gene. The manuscript thus proposed a novel signaling pathway involving PKCalpha, HDAC6 and beta-catenin in the IRF3-mediated gene induction. The findings provide new insight into the mechanism by which IRF3 mediates gene expression upon virus infection.
However, several issues need further illumination.
1. In Fig.1 and Fig.7 , the authors used pharmacal PKC-alpha inhibitor to demonstrate the role of PKC in IRF3-dependent gene expression. What was the vehicle for the pharmacal inhibitor? The vehicle should be used as control in these experiments.
2. The authors declared that Sev infection induced PKC-a translocation from cytosol to the plasma membrane fraction. However, in Fig.1F , the PKC-a translocation to plasma membrane fraction seemed not significant.
3. In Fig.2B , PKC-beta siRNA was not efficient in inhibiting PKC-beta expression. 4. Fig.2 and Fig.7 showed that PKC-a affected IRF3-dependent gene expression. Protein expression of the gene should also be detected by ELISA or Western Blot.
5. On Page 7, the authors declared that PKC-a was specifically involved in the IRF3 mediated induction of type I IFN and other genes after SeV infection. The authors should provide evidence that PKC-a does not affect IRF3-independent gene expression before concluding as that.
6. The manuscript suggested that PKC-a was not involved in RIG-I-dependent signal pathway because PKC-a neither interacted with the known RIG-I signaling mediators nor affected SeVinduced IRF3 activation. Does RIG-I expression affect SeV-induced PKC-a activation? Investigating this issue will be helpful to illuminate the mechanism by which PKC-a functions in anti-virus innate immunity.
7. The data of the manuscript suggested that HDAC6 deacetylated and increased beta-catenin nuclear translocation, which cooperated with IRF3 to bind respective promoter elements to enhance transcription. The authors should provide direct evidence that HDAC6 activation or HDAC6 expression affected the binding of IRF3 the promoter elements.
8. The authors declared that "PKC-a knockdown affected IRF3 mediated transcription without affecting its activation". However, the title of the manuscript is "PKC alpha regulates Sendai virus mediated IRF3 activation through HDAC6 and beta-catenin". They are inconsistent.
1st Revision -authors' response 27 July 2011
Zhu et al PKCa-HDAC6-b-catenin controls Interferon induction

Response to reviewers' comments:
We appreciate the efforts of the editor and the reviewers for their insightful comments on our manuscript, "PKC alpha regulates Sendai virus mediated Interferon induction through HDAC6 and beta-catenin". We are especially happy and encouraged by the interest and enthusiasm shown by all three reviewers. We believe specific suggestions and questions raised by the reviewers have significantly helped to improve the scientific content of the present manuscript. According to the reviewers' suggestions, we have now thoroughly revised the manuscript to enhance clarity, added new results and text to the manuscript in order to address all of the reviewer's concerns. We have added Dr. Carolyn B. Coyne, who performed several Ca2+ signaling experiments as one of the authors. Two of the reviewers were concerned about the PKC translocation data in Fig. 1F . We have repeated the experiment and presented a more convincing figure. Because of the space limitation, some of the additional results have been presented as additional supplementary figures.
Specific concerns:
Reviewer #1: We thank the reviewer for raising an intriguing point. We have addressed this question by infecting cells with several RNA and DNA viruses, Coxsackie virus B (CVB) Vesicular stomatitis virus (VSV) and Herpes simplex virus 1 (HSV1), and monitoring PKC phosphorylation ( Supplementary  Fig. 2 ). Due to institutional regulatory restriction, we were unable to perform Flu virus experiments within the limited time allowed for revision. However, the results of our new studies, which utilize diverse RNA and DNA viruses indicate that PKC-dependent response is seen in both DNA and RNA virus infections and may not be pathogen type specific. This is another important issue. We have now included data demonstrating that manipulation of intracellular Ca2+ homeostasis and signaling does affect SeV mediated IRF3 signaling as measured by ISG56-luciferse activity ( Supplementary Fig. 3 ). When we directly measured [Ca2+] at various stages following SeV infection, we did not detect significant changes in the basal level of cytoplasmic free Ca2+ (2, 3 or 4h post-infection (see attached Fig below. ).
Modulation of Cellular Ca2+ signaling by SeV infection.
HT1080 cells were infected with SeV for the indicated times, washed, and then loaded with Fura2-AM. Following loading, cells were transferred into Ca2+-free medium and images captured at wavelengths of 340nm and 380nm every 10sec for ~5min. Shown are the average 340nm/380nm fluorescence intensity ratios captured from forty cells/condition. At the indicated time, thapsigargin (THP) was added at a final concentration of 0.5 mM. Similar results were obtained in duplicate.
However, when we measured the kinetics of Ca2+ release from ER-derived stores using thapsigargin in SeV-infected cells, we found that SeV infection altered the kinetics of Ca2+ release, particularly at 2-3hrs post-infection (see figure above). These data are striking given that these time points correlate to the activation of PKC shown in the current study. Based upon these observations, we conclude that SeV-induced alterations in Ca2+ mobilization are more complicated than a simple steady state increase in intracellular free Ca2+ levels, which will require detailed follow up studies to elucidate. We now include a detailed discussion on Page 16 of the revised manuscript on literature (Bozym et al, 2010; Collins et al, 2004; Scherbik & Brinton, 2010) regarding the involvement of Ca2+ mobilization during virus infection. Several of these studies, particularly Bozym et al, 2011, demonstrate that there are significant changes in cytoplasmic free Ca2+ levels during CVB infection that are consistent with our current findings that CVB infection induces marked PKC activation. Taken together, these data strongly argue that indeed Ca2+ mobilization caused by virus entry/infection may be the primary inducer of the PKCa-HDAC6-b-catenin pathway.
The speculation on pg 16 about IRF8 compensating for b-cat should be supported if there is a sound basis, or simply removed.
As suggested we have removed this speculation.
Panel 6C very poorly represents a loss of acetylated b-cat after 8hrs of Sendai infection. It is not a robust response and seems unlikely to have a significant biological effect. This should be quantified.
On Page 13 we have provided quantification of this data, which shows significant reduction in acetyl-b-catenin/b-catenin ratio upon SeV infection of vector control cells while, that in PKCa knockdown cells remained same.
All the experiments using nuclear fractionation have control panels illustrating nuclear components, but there is no indication of how much cytosolic contamination is in the nuclear preparations, important to rule out for these experiments. Please provide additional controls.
We have now included immunoblotes with anti-a-tubulin antibodies in all the nuclear fractions.
Reviewer #2:
Fig. 1E. It is claimed in this figure that Sendai virus infection induces PKCalpha activation as detected by phosphorylation. However, there are considerable high levels of phosphorylated PKCalpha prior to infection, and the increase during viral infection is very subtle. These results are not convincing.
We agree with the reviewer that the results of PKC phosphorylation in Fig. 1E by SeV are subtle. To address this, we used several different experimental approaches, such as knockdown etc. to confirm these findings on the specific role of PKCa in this signaling pathway. Additionally, we have now provided PKC activation profiles with other viruses , such as VSV and HSV1, where the effects are more pronounced. A technical limitation with immunoblots is obviously the availability of antibodies. In this study, we used a phospho-PKC (pan) (βII Ser660) Antibody (Cell Signaling Technology #9371) which detects a number of PKC isoforms when phosphorylated at a carboxyterminal residue homologous to serine 660 of PKC β. Therefore, this antibody is not specific for phospho-PKCa, which may result in higher background due to other phospho-PKC isoforms. Furthermore, there is a basal level of phospho-PKC present in many cell lines which may complicate immunoblotting. Nonetheless, we feel that our data show an upregulation of phosphoPKCalpha in virus-infected cells. Fig. 1F are also unconvincing, and importantly, not correlated with the subtle changes in phosphorylated PKCalpha in Fig. 1E We have repeated this experiment and present more convincing data, which show substantial PKCa membrane translocation at 5h post-infection (Fig. 1F) following its activation which peaks at 4h (( Fig. 1F) 
The translocation data of
In the same line, Fig 5C shows that there is a decrease in phosphorylation of HDAC when PKCalpha is silenced even in the absence of Sendai virus infection (compare lines 1 to 3). This would indicate that prior to infection and activation, endogenous PKCalpha has already primed HDAC/betacatenin, and that this pathway, although needed for IRF3-mediated transcription, may not be so dependent on viral activation, at least in the cells used in this study.
This is an interesting point. We have now discussed this issue of background HDAC6 phosphorylation on Page 11, which may be due to the incomplete knockdown and/or the basal levels of PKC activity found in most cell lines. Although it is possible that that in these cells basal levels of endogenous PKCa activity can contribute to the priming of the HDAC6/b-catenin pathway, however the observed signal dependent increase in PKCa translocation, HDAC6 phosphorylation, HDAC6 activity and b-catenin translocation would argue against such scenario.
The model in Fig 7C does not take into account the constitutively association of beta-catenin with PKCalpha
We have now modified the model in Fig. 7C to account for the constitutive association of b-catenin, HDAC6 and PKCa.
Reviewer #3:
1. In Fig.1 and Fig.7 We thank the reviewer for pointing this out. In the previous version we had neglected to mention the vehicle (DMSO) controls that were used in all the inhibitor experiments (Final DMSO concentration ≤ 0.5%). We have now mentioned this in the figure legends. Additionally, we have added DMSO dose responses to ISG56-luciferase induction by both SeV infection and poly(I):poly(C) transfection (Supplementary Fig. 1C and 1D ). Fig.1F , the PKC-a translocation to plasma membrane fraction seemed not significant.
The authors declared that Sev infection induced PKC-a translocation from cytosol to the plasma membrane fraction. However, in
As discussed before we have repeated this experiment and presented a more convincing data.
3. In Fig.2B , PKC-beta siRNA was not efficient in inhibiting PKC-beta expression.
This was due to the poor detection quality of endogenous PKCb by anti-PKCb antibody. In addition to the protein level knockdowns, we had confirmed the specificity of knockdowns by PKCa and PKCb siRNA using quantitative RT-PCR. We have now presented this data in Supplementary Fig.  4A . Fig.2 and Fig.7 showed that PKC-a affected IRF3-dependent gene expression. Protein expression of the gene should also be detected by ELISA or Western Blot.
4.
Western blots for IRF3 dependent genes ISG60 (IFIT3) and/or ISG56 (IFIT1) were provided in Fig.  1 , 2, 3, 5 and 7. However, we have not yet been successful in detecting IFNb using commercially available ELISA kits, in spite of having strong IFNb mRNA induction and positive antiviral bioassays from the same samples. IFNa subtypes are not strongly induced by HEK293 or HT1080 cells upon SeV infection.
On Page 7, the authors declared that PKC-a was specifically involved in the IRF3 mediated induction of type I IFN and other genes after SeV infection. The authors should provide evidence that PKC-a does not affect IRF3-independent gene expression before concluding as that.
We appreciate the reviewer pointing this out. We have now edited this sentence, as well as carefully revised the entire manuscript to not emphasize only IRF3 mediated gene induction. As we had discussed in Page 16 (data included in Supplementary Fig. 4) , that SeV mediated NF-kB activation is also affected by PKCa knockdown. However, dissecting the biochemical mechanism of this block is beyond the scope of this paper.
The manuscript suggested that PKC-a was not involved in RIG-I-dependent signal pathway because PKC-a neither interacted with the known RIG-I signaling mediators nor affected SeVinduced IRF3 activation. Does RIG-I expression affect SeV-induced PKC-a activation?
Investigating this issue will be helpful to illuminate the mechanism by which PKC-a functions in anti-virus innate immunity.
We have now investigated this question and the data are presented in Supplementary Fig. 10 . RIG-I knock down using siRNA did not inhibit SeV mediated PKC phosphorylation although it did inhibit SeV mediated ISG56 induction, thus confirming a functional knockdown. Therefore, we believe PKCa activation is independent of RIG-I expression, which is again supported by the absence of direct interaction of PKCa and RIG-I. We have now corrected the title to address this inconsistency.
2nd Editorial Decision 23 August 2011
Many thanks for submitting the revised version of your manuscript EMBOJ-2011-77837R. After a slight delay, for which I apologise, it has now been seen again by all three referees, whose comments are enclosed below. As you will see, all three reviewers find the study to be substantially improved and are now fully supportive of publication. I am therefore pleased to be able to tell you that we will be able to accept your study to be published in EMBOJ, although I do just have a few minor issues from the editorial side first:
-I think it would be valuable to show the data on ER store Ca release upon infection as a supplementary figure: I realise that you have extensively discussed the literature on this, but including your own data would be useful here. On a similar note, I think you could then include a tentative indication that you think Ca is mediating PKC activation upon SeV infection in the schematic in figure 7: where you have the "?" at present, you could put a "Ca2+?".
-Please can you provide a single PDF comprising all the supplementary information, rather than separate files?
-We now encourage the publication of source data, particularly for electrophoretic gels and blots, with the aim of making primary data more accessible and transparent to the reader. Would you be willing to provide the original, uncropped and unprocessed scans of all gels used in the figures (or at least of key data panels)?These should be labelled with the appropriate figure/panel number, and should have molecular weight markers; further annotation would clearly be useful but is not essential. Ideally, we would need one figure (in jpg or gif format) per figure, which will appear as supplementary files and be directly linked to each main figure. Please let me know if you have any questions about this policy.
Once you have made these final changes and submitted the revised manuscript, we should then be able to accept it for publication without further delay.
Many thanks for choosing EMBOJ for publication of this study, and congratulations on a fine piece of work! Editor The EMBO Journal
REFEREE REPORTS
Referee #1 (Remarks to the Author):
The authors have adequately addressed my initial concerns in this revised manuscript.
